Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

316 recalls, newest first

Class II · Moderate risk

Sertraline Tablets

CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Ongoing cGMP deviation Legacy Pharmaceutical Packaging LLC NDC 68645-523-54 D-0205-2024
Class II · Moderate risk

Nystatin 150 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-1 D-0157-2024
Class II · Moderate risk

Nystatin 2 Bu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-4 D-0156-2024
Class II · Moderate risk

Nystatin 500 Mu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-3 D-0155-2024
Class II · Moderate risk

Nystatin 5bu

Labeling: Label Error on Declared Strength: Assay value on the label is incorrect.

Ongoing Labeling / mix-up Fagron, Inc NDC 51552-0041-5 D-0154-2024
Class I · High risk

Magnum XXL 9800

Marketed without an approved NDA/ANDA: Magnum XXL found to contain undeclared active pharmaceutical ingredient (API) - Sildenafil.

Ongoing Chemical / undeclared Meta Herbal D-0206-2024
Class I · High risk

SANDIMMUNE Oral Solution

Crystallization: bottles of Sandimmune Oral Solution were determined to contain crystals

Ongoing Failed specification Novartis Pharmaceuticals Corporation NDC 0078-0110-22 D-0144-2024

Recalls by year